Targeting ABCG2-mediated drug efflux therefore has emerged as a promising strategy for combating chemoresistance and improving treatment results in cancer patients (Zhang, 2007; Peng et al., 2010; Mo and Zhang, 2012). This evidence concerns the gene ABCG2 and cancer.